36 research outputs found

    Determining the Binding Affinity of Therapeutic Monoclonal Antibodies towards Their Native Unpurified Antigens in Human Serum

    Get PDF
    <div><p>Monoclonal antibodies (mAbs) are a growing segment of therapeutics, yet their <i>in vitro</i> characterization remains challenging. While it is essential that a therapeutic mAb recognizes the native, physiologically occurring epitope, the generation and selection of mAbs often rely on the use of purified recombinant versions of the antigen that may display non-native epitopes. Here, we present a method to measure both, the binding affinity of a therapeutic mAb towards its native unpurified antigen in human serum, and the antigen’s endogenous concentration, by combining the kinetic exclusion assay and Biacore’s calibration free concentration analysis. To illustrate the broad utility of our method, we studied a panel of mAbs raised against three disparate soluble antigens that are abundant in the serum of healthy donors: proprotein convertase subtilisin/kexin type 9 (PCSK9), progranulin (PGRN), and fatty acid binding protein (FABP4). We also determined the affinity of each mAb towards its purified recombinant antigen and assessed whether the interactions were pH-dependent. Of the six mAbs studied, three did not appear to discriminate between the serum and recombinant forms of the antigen; one mAb bound serum antigen with a higher affinity than recombinant antigen; and two mAbs displayed a different affinity for serum antigen that could be explained by a pH-dependent interaction. Our results highlight the importance of taking pH into account when measuring the affinities of mAbs towards their serum antigens, since the pH of serum samples becomes increasingly alkaline upon aerobic handling. </p> </div

    Influence of pH on the apparent affinity (top) and apparent activity (bottom) of different mAbs towards their purified recombinant antigens.

    No full text
    <p>The K<sub>D</sub> values and mAb activities for each interaction were obtained from a single curve KinExA analysis performed at different pH values that spanned the pH range encountered during serum experiments. The bars represent the best fit values and the error bars represent the 95% confidence interval. The arrows indicate the trend observed with increasing pH and the range of best fit values for K<sub>D</sub> and activity. Only sweet spot experiments enabled a determination of both the K<sub>D</sub> and the mAb activity (no mAb activity is reported for 19F7 and 33B12 because those curves were mostly K<sub>D</sub>-controlled). The antigen concentrations used were 128 pM rhPCSK9, 42 pM rhPGRN, 21 pM rhPGRN, 100 pM rhFABP4, and 1nM rhFABP4 (from left to right).</p

    Human serum titrated with anti-PCSK9 mAb J16.

    No full text
    <p>(A) Raw data trace of fluorescence (in Volts) as a function of time recorded by the KinExA instrument for a typical experiment: (I) packing of mAb-coated beads inside the flow cell; (II) baseline signal; (III) auto-fluorescence signal obtained from serum components (presumably porphyrins); (IV) buffer wash; (V) detection of bead-captured PCSK9 with a Dylight-labeled mAb; and (VI) buffer wash, after which the final fluorescence signal for bead-captured PCSK9 is recorded (relative to the baseline signal). (B) Global fit of normalized data obtained from titrating J16 into different dilutions of serum prepared in PBS. (C) Error plots for K<sub>D</sub> and PCSK9 concentration for the global analysis in panel B with best fit values (solid line) and 95% confidence interval (dotted lines). (D) Comparison of the fits obtained for single-curve and multi-curve (global) analysis of the data in panel B. The PCSK9 concentration is back-calculated for undiluted serum. Open and closed symbols indicate independent experiments performed with the same dilution factor. </p

    Kinetic analysis of anti-PGRN mAbs 2B2 (left) and 19F7 (right) in TBST buffers at different pH values.

    No full text
    <p>The data were collected on a ProteOn XPR36 biosensor by injecting a dilution series of rhPGRN (0.8, 2.4, 7.1, 21.3, and 64 nM) over amine-coupled mAbs. Double-referenced sensorgrams (colored lines) obtained from two ligand channels per mAb were fit globally to a 1:1 binding model with mass transport limitation (fit shown in black); the results from one channel per mAb is shown along with the global best fit K<sub>D</sub>.</p

    DKK1/DS4 interaction studied in the fixed antibody and fixed antigen assay orientations on the KinExA.

    No full text
    <p>(A) In the fixed antibody orientation, a series of samples is prepared by titrating DKK into a fixed concentration of antibody binding sites. After sample equilibration, free antibody binding sites are captured on beads and detected by a fluorescently labeled anti-species antibody. In our modified KinExA method, the beads are coated with a murine anti-idiotypic mAb instead of antigen. (B) In the fixed antigen orientation, a series of samples is prepared by titrating the antibody into a fixed DKK concentration. Free DKK in equilibrated samples is captured on antibody-coated beads and detected with a customized sandwiching mAb that is fluorescently-labeled (one step detection) or unlabeled and followed by a fluorescently-labeled reagent (two step detection); see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0036261#s4" target="_blank">Materials and Methods</a>. (C) Global analysis of DS4's interaction with human DKK1 in the fixed antibody orientation. The “unknown ligand” model in the KinExA software automatically corrects the concentration of the titrated component with the best fit for its apparent activity, so that the x-axis shows the antigen's active concentration, rather than its nominal concentration. (D) Global analysis of DS4's interaction with human DKK1 in the fixed antigen orientation. For both panels C and D, the nominal concentration of the fixed binding partner is indicated per titration curve; in panel D, the best fit binding site concentration is indicated in parentheses. The apparent K<sub>D</sub> values for panels C and D were 0.49 pM and 0.42 pM, respectively (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0036261#pone-0036261-t001" target="_blank">Table 1</a>).</p

    Technology comparison of epitope binning assays on sixteen anti-hPGRN mAbs using complementary assay formats.

    No full text
    <p>Heat maps for (A) SPRi – classical sandwich, (B) SPRi – premix, (C) BLI – classical sandwich, and (D) BLI – premix experiments. (E) Node plot of the deduced bin assignments from panels A–D. All experiments were conducted on a 96-ligand array (i.e., sixteen mAbs coupled onto six surfaces each). Sixteen mAbs were each used as analyte (A) up to six times, (B) up to five times, (C) once, and (D) twice. In the heat maps, the rows represent the ligands and the columns represent the analytes, in the same order. Analyte/ligand pairs are assigned as blocked (red), not blocked (green), or ambiguous (yellow), and self-blocks are outlined with a black box. Panels A, B and D each represent the results for a single experiment, whereas panel C represents the consolidated results from three separate experiments on the same sensors, because the autosampler capacity allowed for a maximum of five mAb analytes per experiment. Grey rows in panels A and B indicate inactive ligands and the grey columns indicate mAbs that were not tested as analyte.</p

    BLI analysis of sixteen anti-hPGRN mAbs using complementary epitope binning assay formats.

    No full text
    <p>(A) Overlay plot for the coupling of 96 mAbs on parallel sensors (six replicate sets of sixteen mAbs). (B) Sensorgrams obtained from a classical sandwich assay on six sensors coupled with mAb 1B8 (the sensorgrams cluster into three pairs of curves because the couplings were performed on duplicate sensors in three consecutive runs). Analytes highlighted in green have different epitopes than the ligand (i.e., 1B8 does not block 27D5, 19F7, 20G6, or 19C5) whereas the analyte highlighted in red has an epitope that overlaps with that of the ligand (i.e., 1B8 blocks 28H6). (C) Sensorgrams obtained from a premix assay on six sensors coupled with mAb 2B2 (the same analyte wells were tested in duplicate cycles). Panels B and C are representative of the much larger data sets generated in those experiments. Response data are aligned to zero at the start of the sensorgrams.</p
    corecore